Refine by
Drug Development Program Articles & Analysis
20 news found
“This achievement demonstrates our commitment to providing our customers with the highest quality materials for their drug development programs. We are confident that this registration will help to streamline and accelerate the development of new ...
This improved outlook comes amid the company’s potential blockbuster drugs tracking ahead of schedule and targeted investments in Research and Development (R&D) replenishing its pharmaceutical development pipeline. ...
ByBayer AG
(“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. ...
Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP is MDA’s drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular disorders. MVP ...
BynVector
(CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide a product development report on its Rotigotine transdermal (“TDS”) patch. The Company’s Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). ...
Fluidda, leader in the field of Functional Respiratory Imaging and developer of the medical device Broncholab®, today announced an exclusive collaboration with Nanopharm, an Aptar Pharma company and a leader in contract research and development services for orally inhaled and nasal drug products (OINDPs). ...
ByFluidda
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...
About VeriSIM Life VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug ...
(Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and ...
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. The company has recently announced Protein Drug Modification Analysis service to help researchers determine the modification type, modification site, and modification structure of protein drugs. Mature protein medicines have complete ...
Morriss has a track record of developing successful drug programs and building clinical teams for all phases of development. ...
The area of drug development is a veritable minefield with many junctures where a project can come to an abrupt end. ...
The company recently unveiled its growing portfolio of emerging joint venture companies, with drug development programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. ...
As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group. Moberg brings 30+ years of expertise to Bexson, ...
Actym's SAB comprises world-renowned subject matter experts in immuno-oncology, innate immunity, microbiology, novel drug discovery and development. "We are pleased to welcome Drs. Fong and Streuli, two globally recognized experts in immuno-oncology, to Actym's world-class Scientific Advisory Board," said Dr. ...
It is estimated that each year in the United States more than 180,000 women undergo a lumpectomy, of which one-third (approximately 60,000) are repeat surgeries with the goal of achieving negative margins.1 Beyond that, of the estimated 100,000 women who choose a mastectomy, many choose it for fear of incomplete initial lumpectomy or due to an initial attempt at a lumpectomy that resulted in ...
GC Pharma’s partnership with Atomwise will enable the expansion of its hemophilia business and launch multiple discovery programs to develop a small molecule therapy for hemophilia and other indications. ...
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) ...
My partner Maryanna Saenko and I are excited to be joining them on a journey to modernize drug development by using AI to design and derisk drug development programs up front, instead of relying on trial-and-error experiments that are fraught with time delays and high ...
This game changing capability provides a much more reliable predictor for the status of your immune system than any other method and could lead to fundamental changes in drug & vaccine development and medical practice. The immune system is the critical function in the body for managing health. ...